Summary
Orthopedic surgery and sports medicine sit within a large musculoskeletal care market. Worldwide orthopedic sales reached USD 64.9 billion in the latest period, up 4.9% 4. The strongest verified evidence concerns the U.S. workforce: a peer-reviewed simulation projects supply falling 2% while demand rises 10%, lowering adequacy to 89% under the status quo 1. Shortages are expected to be greatest in nonmetropolitan areas 2. Outpatient migration, robotics and market concentration shape competition [S5, S7]. Principal risks include an aging surgeon workforce, geographic access gaps, supplier concentration and a lack of verified data on cost, quality, waiting times and equity. Outlook: capacity pressure is likely to intensify unless delivery models change, and stakeholders should plan around ambulatory capacity and workforce supply.
Key findings
-
1
U.S. orthopaedic workforce supply is projected to fall while demand rises
The status quo projection shows supply declining by 510 FTEs (2%), overall adequacy falling from 100% to 89%, and demand rising by 3,140 FTEs (10%).
Confidence: High -
2
Projected shortages are concentrated in nonmetropolitan areas and certain states
Supply is projected to fall 5.2% while demand rises 7.1%. West Virginia and Arkansas were among states with the lowest projected adequacy in the latest period.
Confidence: Medium -
3
Worldwide orthopedic revenue is concentrated among a few large companies
Eight companies with over USD 1 billion in annual orthopedic sales control about two-thirds of the worldwide market, with combined revenue of USD 43.3 billion.
Confidence: Medium -
4
Outpatient settings are forecast to absorb more knee and hip replacements
The Ambulatory Surgery Center Association expects more than 50% of total knee and hip replacements to be performed in outpatient settings. This is a forecast.
Confidence: Medium -
5
Robotic surgery scale is reported by a vendor, and its clinical standing is not independently verified
Stryker reports 3,000 MAKO systems installed worldwide and states that robotic surgery is becoming the standard of care in the U.S. The standard-of-care statement is a vendor claim.
Confidence: Qualitative -
6
Sports medicine market estimates conflict across publishers
Two market research estimates put the global sports medicine market at USD 8.01 billion and USD 7.5 billion for the latest period, with different growth projections. Neither should be treated as definitive.
Confidence: Qualitative
1Industry definition and scope
This report covers orthopedic surgery, which treats conditions of bones, joints, ligaments, tendons and muscles through operative and non-operative care, and sports medicine, which addresses injury, rehabilitation and care of active patients. The source pack treats the two areas as adjacent service lines, and this report follows that framing. The boundary is the writer's interpretation, not a formal definition from a cited source.
Geographic scope is split by evidence type. Workforce, demand and outpatient-setting evidence is United States only [S1, S2, S6, S7]. Market sizing is global [S4, S8, S9], except where a U.S. market estimate is cited [S6, S7]. Market estimates differ by publisher, so no single publisher's figure is treated as the correct value.
Terminology: sources use both orthopedic and orthopaedic, which this report treats as equivalent. Workforce is measured in full-time equivalents (FTEs), which is not the same as headcount. Segments discussed include implants and devices, robotic platforms, single-use consumables, and care settings such as hospitals and ambulatory surgery centers.
The reporting period is the latest available data. All projections are forecasts from the cited publishers and run to the horizon each source states.
Scope boundaries are the writer's interpretation of the source pack.
Assumptions behind these figures
- Orthopedic and orthopaedic are treated as the same term.
- Workforce figures are full-time equivalents unless stated as headcount.
2Market size, structure and value chain
Worldwide orthopedic sales reached USD 64.9 billion in the latest period, up 4.9% from the prior year 4. This is an observed trade publication figure. Eight companies with more than USD 1 billion in annual orthopedic sales held combined revenue of USD 43.3 billion, which the source describes as about two-thirds of the worldwide market 4. The market is concentrated at the top.
The U.S. orthopedics market was valued at USD 59.2 billion and is projected to reach USD 86.4 billion 6. The source is an investment firm report, and the projection is a forecast. The U.S. and global figures come from different publishers and geographies, so they should not be added, subtracted or treated as shares of each other.
Sports medicine is smaller and less consistently measured. Fortune Business Insights estimates the global market at USD 8.01 billion, projected to reach USD 18.42 billion 8. Global Market Insights estimates USD 7.5 billion, projected to reach USD 15 billion 9. Both are market research estimates. North America held 41.53% of the global sports medicine market in the latest period 8, an observed share.
Structure and value chain (writer's interpretation): the chain runs from device and implant makers and robotic platform suppliers, through distributors and consumables, to providers and payers. Hospitals and ambulatory surgery centers held 75.5% of the U.S. orthopedic end-user market 7, an observed share. The pack contains no verified payer or reimbursement breakdown. Conmed reported about 86% of revenue as single-use, recurring revenue 5, which indicates how much of that model depends on consumables rather than one-time equipment sales.
- Worldwide orthopedic sales 64.9USD billion Observed Global, Latest available data [4]
- Combined revenue of eight companies with over USD 1 billion in orthopedic sales 43.3USD billion Observed Global, Latest available data [4]
- Share of U.S. orthopedic end-user market held by hospitals and ambulatory surgery centers 75.5percent Observed United States, Latest available data [7]
Market figures are reported as published. Where publishers conflict, both are shown and no single value is adopted.
Assumptions behind these figures
- Global and U.S. market figures are not treated as subsets of each other.
- Publisher estimates for sports medicine are not combined.
3Customers, demand and adoption
Older adults are a major source of demand. Adults over 65 are 17.3% of the U.S. population but generate 37.0% of diagnostic tests and 34.0% of inpatient procedures 6. These are observed figures from a market report, not a clinical utilization study, so they describe the share of activity rather than individual patient need.
Knee and hip replacement volumes are expected to double, according to the same investment report 6. The source gives no baseline in the text, so the scale of the increase cannot be checked. Registry procedure counts were reviewed but are cumulative across multiple years, so they are not used here as annual volumes.
Demand for orthopaedic surgeon capacity is projected to rise by 3,140 FTEs, or 10%, under the status quo scenario 1, and by 7.1% in a separate simulation 2. Rising demand is therefore a central pressure on the workforce.
Care setting is shifting. The Ambulatory Surgery Center Association expects more than 50% of total knee and hip replacements to be performed in outpatient settings 7. This is a forecast reported by a market research firm. Purchasing criteria such as cost, convenience and surgeon choice are not measured in the pack, so this report does not rank them. Barriers such as waiting times and out-of-pocket costs are not verified.
- Share of diagnostic tests generated by adults over 65 37.0percent Observed United States, Current market report [6]
No waiting-time, out-of-pocket or patient preference data was verified for this section.
Assumptions behind these figures
- Activity shares describe utilization, not clinical need.
4Competitive landscape and key players
Competition is concentrated. Eight companies with over USD 1 billion in orthopedic sales dominate worldwide revenue 4. The pack provides company-level data for only a few firms, so the comparison below is partial and relies on company-reported and trade-reported figures.
Stryker reported organic revenue growth of 10.3% to USD 25.1 billion and had 3,000 MAKO robotic systems installed worldwide at the end of the latest period 5. The company states that MAKO robotic surgery is becoming the standard of care in the U.S. 5. This is a vendor claim reported in an investment research paper, not an independently verified finding.
Conmed's roughly 86% recurring single-use revenue 5 shows a business model built on consumables and repeat use. Treace Medical's Lapiplasty volumes faced pressure as surgeons and patients moved toward minimally invasive osteotomies 4, an example of how procedure preference can shift revenue within one product category.
Provider types differ in role. Hospitals and ambulatory surgery centers are the main end-user group 7. The pack contains no verified comparison of public, private and community providers on cost, quality, safety or outcomes, so a fair ranking of provider types is not possible.
Competitive pressures (writer's interpretation): scale suppliers can fund platform investment, while smaller firms may depend on procedure niches that can shift quickly. In sports medicine, the pack provides market size and regional share but no company-level competitor data [S8, S9].
- Robotic systems installed worldwide by one orthopedic supplier 3000MAKO systems Observed Global, End of latest available period [5]
Company examples draw on trade, investment and company-reported sources. Comparable financial data for all named firms was not verified.
Assumptions behind these figures
- Company examples are illustrative of business models, not a ranking of firms.
5Technology, operations and workforce
Robotic platforms are the most visible technology in the pack. Stryker's 3,000 installed MAKO systems 5 show scale, but the pack contains no verified adoption rates by procedure, outcome comparison or cost-effectiveness data. Minimally invasive osteotomy approaches are also reshaping procedure mix 4. Established practice and emerging approaches should be distinguished: robotics and minimally invasive methods appear in market data, while long-term outcome evidence is not verified in the pack.
Workforce is the strongest verified constraint. A peer-reviewed simulation projects that U.S. orthopaedic surgeon supply will fall by 510 FTEs, a 2% decline, while overall adequacy falls from 100% to 89% under the status quo 1. A cross-sectional study projects supply down 5.2% against a 7.1% rise in demand 2. A federal workforce simulation covering 35 specialties projects a 12% orthopedic shortage 3.
Aging is a supply risk. Close to 60% of orthopedic surgeons in active practice are 55 or older, according to a staffing company blog 10. That source is a company blog citing projections and carries less weight than the peer-reviewed sources. The Association of American Medical Colleges projects a shortage of up to 23,000 surgeons 10, a forecast. Bureau of Labor Statistics data show a decline in orthopedic surgeons, except pediatric, 3, an observed trend.
Digital health, AI adoption and productivity measures are not verified in the pack. The table compares workforce projections by metric. These metrics are not interchangeable and should not be added together.
- Projected overall U.S. orthopaedic workforce adequacy under the status quo 89percent adequacy Forecast United States, Status quo projection, latest available data [1]
| Measure | Reported figure | Value type | Source |
|---|---|---|---|
| Supply change, U.S. orthopaedic surgeons | Decline of 510 FTEs (2%) | Forecast | S1 |
| Overall workforce adequacy under status quo | 89% | Forecast | S1 |
| Demand change under status quo | Increase of 3,140 FTEs (10%) | Forecast | S1 |
| Supply change compared with demand change | Supply down 5.2%; demand up 7.1% | Forecast | S2 |
| Orthopedic shortage in federal model of 35 specialties | 12% | Forecast | S3 |
| Projected surgeon shortage (AAMC) | Up to 23,000 surgeons | Forecast | S10 |
The S10 figures come from a staffing company blog and are shown with lower weight.
Assumptions behind these figures
- Supply, adequacy and demand measures come from different models and are not additive.
6Regulation, standards, risk and sustainability
Jurisdiction: this regulatory discussion is limited to the United States. The source pack does not contain verified regulatory texts, device authorization rules, professional licensing standards, payment rules or safety standards for orthopedic surgery or sports medicine. This report therefore does not classify any rule as binding, proposed or voluntary. Readers should consult primary regulatory sources for that classification.
Workforce risk is geographic. Shortages are expected to be greatest in nonmetropolitan areas and in certain states 2. The simulation model's lowest projected adequacy in the latest period included West Virginia at 60.9% and Arkansas at 69.7% 2, observed figures. Continuity of care in these areas is a material operational risk.
Supplier concentration is a market risk. Eight companies control about two-thirds of worldwide orthopedic sales 4. Recurring consumable revenue, as reported by Conmed 5, creates dependence on continued procedure volumes and device supply. Shifts in procedure mix can reduce volumes for individual products 4.
Sports medicine access is limited in some settings. A dearth of trained healthcare professionals in developing countries restricts access to quality sports medicine care 9. This is an observed qualitative finding from a market research publisher, and no verified quantity is available.
Privacy and ethics: this report uses only aggregate market and workforce data. No patient-level data was used, and nothing here is individual medical advice. Environmental and social factors, such as waste from single-use products, are not measured in the pack; any such implication is the writer's interpretation.
Risk points are drawn from workforce, market and access evidence in the pack.
Assumptions behind these figures
- Regulatory classification is not attempted because no regulatory sources are in the pack.
7Challenges, opportunities and case examples
Major constraints include a projected supply decline against rising demand 1, geographic shortages 2, an aging workforce 10 and concentrated supply 4. Access, waiting times, cost and outcomes are not verified, so these pressures are stated only as workforce and market evidence.
Opportunities include ambulatory settings, which may absorb a growing share of knee and hip replacements, with a forecast above 50% in outpatient settings 7. Robotics has scale, with 3,000 installed systems reported 5. Sports medicine estimates point to growth, although the estimates conflict and both are market research projections [S8, S9].
Case example 1: Stryker. Revenue grew 10.3% organically to USD 25.1 billion, and the company reports 3,000 MAKO systems installed 5. Its standard-of-care claim is a vendor position. The example shows commercial scale, not verified clinical superiority.
Case example 2: Treace Medical. Lapiplasty volumes came under pressure as surgeons and patients shifted toward minimally invasive osteotomies 4. The example shows how procedure preference can shift demand within a product category. The pack does not provide Treace's financial data.
Case example 3: Conmed. About 86% of revenue is single-use and recurring 5, an example of a consumables-led model. The pack provides no outcome data for any of these companies, so the examples describe commercial positions only, and comparable market data for all three firms is limited.
Examples are drawn from trade, investment and company-reported sources and are not independently audited.
Assumptions behind these figures
- Case examples describe commercial positions and are not outcome evidence.
8Outlook and strategic implications
Near term: the status quo projection expects workforce adequacy to decline from 100% to 89% as demand grows 1. This is the most defensible outlook in the pack, although it is a single scenario and no alternative scenarios are verified.
Medium term: outpatient migration is expected to continue, with more than half of knee and hip replacements in outpatient settings forecast 7. Robotics adoption may grow given the installed base reported by Stryker 5, but that claim is a vendor position.
Uncertainty: market size estimates differ across publishers [S8, S9], and sports medicine forecasts conflict. Workforce projections come from models whose assumptions are not restated in the pack, so the forecasts are plausible but sensitive to inputs.
Implications (writer's interpretation): providers should plan ambulatory capacity and workforce pipelines, especially for nonmetropolitan areas. Suppliers should expect demand to shift across procedures and settings. Payers and policymakers need verified data on payment, waiting times and outcomes before judging access. Researchers should address the gaps listed in the methodology callout.
This outlook is an industry assessment, not individual medical, legal or investment advice.
Assumptions behind these figures
- Forecasts are treated as projections, not outcomes.
9Conclusion
The best-supported finding is a widening gap between orthopaedic workforce supply and demand, concentrated in nonmetropolitan areas [S1, S2]. Market growth and robotics are real but largely reported by vendors and publishers. Outcomes, cost, access and equity remain unverified, so quality and affordability cannot yet be fully assessed.
Central assessment based on the verified source pack.
How this was built
This report uses only the verified source pack. Workforce evidence is U.S. only. Market sizing is global, with publisher estimates shown separately and not combined. Forecasts are labeled as forecasts, and vendor and company claims are labeled as such.
Limits to keep in mind
- No verified global or non-U.S. orthopedic workforce adequacy data was retrieved; workforce evidence is U.S. only.
- Market size estimates differ widely across publishers; no single sports medicine figure was adopted, and the two cited estimates conflict.
- No verified waiting-time, wait-list or outcome data for orthopedic procedures was retrieved.
- No verified comparison of public, private and community providers on cost, quality or outcomes was retrieved.
- No verified reimbursement or Medicare payment data for orthopedic procedures was retrieved.
- No verified equity or affordability data, such as out-of-pocket costs by income or race, was retrieved.
Sources
-
1
Analyzing Orthopaedic Workforce Trends in an Ever-changing Landscape
pubmed.ncbi.nlm.nih.gov -
2
Geographic Disparities in the Adequacy of the Orthopaedic Surgery Workforce Relative to Other Musculoskeletal Medicine Specialties
pubmed.ncbi.nlm.nih.gov -
3
Orthopedics faces 12% shortage in the latest projection
beckersspine.com -
4
Orthopedic Market Overview
orthoworld.com -
5
Orthopedics Market, latest available edition
gabelli.com -
6
Orthopedic Market Insights, Spring edition
hydeparkcapital.com -
7
U.S Orthopedic Market Size, Share & Trends, latest edition
marketdataforecast.com -
8
Sports Medicine Market Size, Share & Growth Report, latest edition
fortunebusinessinsights.com -
9
Sports Medicine Market Size & Share, Growth Report, latest edition
gminsights.com -
10
Orthopedic Surgeon Shortage Is Looming (AMN Healthcare blog)
amnhealthcare.com